ENSURE-AF Trial Supports Edoxaban for Electrical Cardioversion

ROME — Results of the largest-ever randomized clinical trial of anticoagulation for electrical cardioversion of patients with nonvalvular atrial fibrillation demonstrate that edoxaban is a safe, effective, and convenient alternative to the standard strategy of enoxaparin as a bridge to warfarin.
Source: Caring for the Ages - Category: Health Management Authors: Source Type: news